Navigation Links
Mindray Announces First Quarter 2011 Financial Results
Date:5/9/2011

lion in cash and cash equivalents, and short-term investments as compared to $433.5 million as of December 31, 2010. Net cash generated from operating activities and net cash outflow for capital expenditures during the quarter were $32.3 million and $27.3 million respectively.

As of March 31, 2011, the company had 6,587 employees.

Business Outlook for Full Year 2011The company maintains its full year guidance and expects its full year 2011 net revenues to be more than 16% higher than its full year 2010 net revenues.

The company continues to expect its full year 2011 non-GAAP net income to grow more than 10% over its non-GAAP net income for full year 2010. This guidance excludes the tax benefits related to the key software enterprise status ($8.6 million recognized in the first quarter of 2010 and $7.6 million recorded in the first quarter of 2011) and assumes a corporate income tax rate of 15% applicable to the Shenzhen subsidiary.

The company expects its capital expenditure for 2011 to remain in the range of $70 million to $80 million.

The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

"We are maintaining our guidance at this time. In the first quarter, we were pleased with our performance in the international markets, as well as the sales improvement resulting from our strategic initiatives in China," commented Li Xiting, Mindray's president and co-chief executive officer. "The overall growth prospects of our key international markets continue to be positive, although we are closely monitoring the political situations in the Middle East and Africa. We also firmly believe that China's healthcare sector investment environment remains favorable, which bodes well for leading companies like Mindray. Based on our commitment to invest in international markets, the implementation of our initiatives
'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
2. Mindray to Report First Quarter 2011 Financial Results on May 9, 2011
3. Mindray Medical to Exhibit New Products at 65th China International Medical Equipment Fair
4. Mindray Appoints Mr. Jie Liu as Chief Financial Officer
5. Mindray Medical to Present at the 14th Annual Credit Suisse Asian Investment Conference on March 21-25
6. Mindray Medical to Acquire a Controlling Stake in Shenke Medical
7. Mindray Announces 2010 Fourth Quarter and Full Year Results
8. Mindray Announces FDA 510(k) Clearance of Its A5 Anesthesia System
9. Mindray to Report Fourth Quarter and Full Year 2010 Financial Results on February 28, 2011
10. Mindray Receives its Largest Order of Patients Monitors in Canada
11. Mindray Medical to Exhibit at Arab Health 2011 in Dubai from January 24-27
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... MEETING, Pa. , July 23, 2014 ... INO) today announced successful results from its ... VGX-3100 in women with biopsy-proven cervical intraepithelial ... (HPV) types 16 or 18. Treatment with ... regression of CIN2/3 to CIN1 or no ...
(Date:7/23/2014)... 23, 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: ... on its expertise in opioid antagonists, announced today ... application ("IND") with respect to its naloxone-based opioid ... that it has received an additional commitment from ... of the National Institutes of Health ("NIH"), to ...
(Date:7/23/2014)... Calif. , July 23, 2014  Cardica, Inc. (Nasdaq: ... financial results for its fiscal fourth quarter and year ended ... markets close. Cardica,s management will host a conference call at ... provide an update on the company,s business. Conference ... 7, 2014, at 4:30 p.m. Eastern Time via phone, please ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2
(Date:7/23/2014)... China,s Northwest Agricultural and Forestry University in Shaanxi province, ... memorandum of agreement that lays the groundwork for establishing ... China. , The signing ceremony was held in the ... officials of the U.S. Department of Agriculture and China,s ... a landmark event for UC Davis and for our ...
(Date:7/23/2014)... Angeles, CA (PRWEB) July 23, 2014 ... practices delivering Enhanced External Counterpulsation (EECP), is ... who receives EECP therapy at the health center. ... ischemic heart disease. Since receiving ongoing EECP therapy since ... , When Sara Soulati, CEO of Global Cardio Care, ...
(Date:7/23/2014)... Unlocking the secrets to better treating the pernicious disorders ... to a paper from American University,s Center for Behavioral ... treating obesity with therapies aimed at areas of the ... focus on the hippocampus could play a role in ... diseases, therapies and preventive measures often fall short. This ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July 23, ... an additional side benefit -- it may improve urinary ... The study found that nearly half of women ... to the procedure. After surgery, most of those women ... study researcher Dr. Leslee Subak, professor of obstetrics, gynecology ...
(Date:7/23/2014)... catalog the molecular causes of stomach cancer, scientists, ... four subtypes of tumors based on shared mutations ... classification promises to advance clinical research to develop ... , In a report in Nature , ... said they analyzed 295 samples of gastric (stomach) ...
Breaking Medicine News(10 mins):Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 2Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 3Health News:New view of stomach cancer could hasten better therapies 2Health News:New view of stomach cancer could hasten better therapies 3
... in low sunlight areas are more likely to experience ... same environment. Researchers believe that these findings should change ... study shows that across the board vitamin D recommendations ... M.D., M.B.A., clinical instructor in the department of urology ...
... well-known risk factor for heart disease. Researchers at the ... participated in an international study of 200,000 Europeans which ... pressure. The discovery, presented in Nature, is an important ... people worldwide suffer from high blood pressure and are ...
... in areas with low sunlight are up to 3 ... men and should take high levels of Vitamin D supplements, ... of Medicine. "This study shows that the current ... Vitamin D don,t work," said Adam Murphy, M.D., a clinical ...
... Tenn. September 19, 2011) The largest study ever of ... tumors carried extra copies of specific genes linked to cancer ... Hospital investigators. The findings identify possible new targets ... diffuse intrinsic pontine glioma (DIPG). Current survival rates for children ...
... , MONDAY, Sept. 19 (HealthDay News) -- Obese 8- ... than their normal-weight peers, a new study finds. In ... of height and weight, at ages 4 and 5 and ... out questionnaires that assessed children,s mental health and health-related quality ...
... HealthDay Reporter , MONDAY, Sept. 19 (HealthDay News) -- ... treating varicose veins, it appears that recurrence of one ... laser treatment, German researchers report. Varicose veins are ... legs. As many as 35 percent of adults suffer ...
Cached Medicine News:Health News:African-American men living in poor sunlight areas at risk for vitamin D deficiency 2Health News:Genetic factors behind high blood pressure 2Health News:One size doesn't fit all for vitamin D and men 2Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 2Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 3Health News:Obese Kids May Face Social, Emotional Woes 2Health News:Obese Kids May Face Social, Emotional Woes 3Health News:Two Varicose Veins Treatments Equally Effective 2Health News:Two Varicose Veins Treatments Equally Effective 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: